Peptides

A synthetic peptide for use as a blocking control in assays to test for specificity of MAT2B antibody, catalog no. 70R-3455

A synthetic peptide for use as a blocking control in assays to test for specificity of PLCD1 antibody, catalog no. 70R-5826

A synthetic peptide for use as a blocking control in assays to test for specificity of EIF4H antibody, catalog no. 70R-4728

A synthetic peptide for use as a blocking control in assays to test for specificity of CLDN2 antibody, catalog no. 20R-1258

A synthetic peptide for use as a blocking control in assays to test for specificity of ZCCHC13 antibody, catalog no. 70R-4279

A synthetic peptide for use as a blocking control in assays to test for specificity of MTHFS antibody, catalog no. 70R-3776

A synthetic peptide for use as a blocking control in assays to test for specificity of Aldh4a1 antibody, catalog no. 70R-8633

A synthetic peptide for use as a blocking control in assays to test for specificity of Zfp275 antibody, catalog no. 70R-8773

A synthetic peptide for use as a blocking control in assays to test for specificity of EIF2C4 antibody, catalog no. 70R-3041

A synthetic peptide for use as a blocking control in assays to test for specificity of Ercc1 antibody, catalog no. 70R-9364

A synthetic peptide for use as a blocking control in assays to test for specificity of NEK11 antibody, catalog no. 70R-2292

A synthetic peptide for use as a blocking control in assays to test for specificity of ACADS antibody, catalog no. 70R-2317

A synthetic peptide for use as a blocking control in assays to test for specificity of SMU1 antibody, catalog no. 70R-4370

A synthetic peptide for use as a blocking control in assays to test for specificity of C2orf28 antibody, catalog no. 70R-7836

A synthetic peptide for use as a blocking control in assays to test for specificity of LAP3 antibody, catalog no. 70R-2902

A synthetic peptide for use as a blocking control in assays to test for specificity of CDK5 antibody, catalog no. 20R-1201

A synthetic peptide for use as a blocking control in assays to test for specificity of C21orf13 antibody, catalog no. 70R-1973

A synthetic peptide for use as a blocking control in assays to test for specificity of FBLN1 antibody, catalog no. 70R-5356

A synthetic peptide for use as a blocking control in assays to test for specificity of PAFAH1B1 antibody, catalog no. 70R-5657

A synthetic peptide for use as a blocking control in assays to test for specificity of DPH2 antibody, catalog no. 70R-3392

A synthetic peptide for use as a blocking control in assays to test for specificity of TNFRSF9 antibody, catalog no. 70R-10166

A synthetic peptide for use as a blocking control in assays to test for specificity of CHIA antibody, catalog no. 70R-5921

A synthetic peptide for use as a blocking control in assays to test for specificity of MSH5 antibody, catalog no. 70R-5575

A synthetic peptide for use as a blocking control in assays to test for specificity of VISA antibody, catalog no. 70R-6463

A synthetic peptide for use as a blocking control in assays to test for specificity of GNAI3 antibody, catalog no. 70R-9627

A synthetic peptide for use as a blocking control in assays to test for specificity of DENND2C antibody, catalog no. 70R-3785

A synthetic peptide for use as a blocking control in assays to test for specificity of Cyb5r1 antibody, catalog no. 70R-8676

A synthetic peptide for use as a blocking control in assays to test for specificity of CGB antibody, catalog no. 70R-9986

A synthetic peptide for use as a blocking control in assays to test for specificity of PRKACA antibody, catalog no. 70R-4594

A synthetic peptide for use as a blocking control in assays to test for specificity of FLJ44894 antibody, catalog no. 70R-8899

A synthetic peptide for use as a blocking control in assays to test for specificity of SORD antibody, catalog no. 70R-10245

A synthetic peptide for use as a blocking control in assays to test for specificity of Gcom1 antibody, catalog no. 70R-3275

A synthetic peptide for use as a blocking control in assays to test for specificity of TAPBP antibody, catalog no. 70R-6000

A synthetic peptide for use as a blocking control in assays to test for specificity of BMP2K antibody, catalog no. 70R-1033

Custom research peptide; min purity 95%.

Azido-dPEG®3-Amine is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. Azido-dPEG®3-Amine is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

Bovine Serum Albumin (BSA) is a protein that is used in the pharmaceutical industry as a research tool and an immunological reagent. BSA can be used to bind, stabilize, and prevent denaturation of other proteins in the laboratory. It has been shown to inhibit ion channels and ligand-gated ion channels, which are important for membrane potentials. BSA is also an activator of receptor tyrosine kinases, which are involved in cell signaling pathways.

Antipain is a proteolytic enzyme that hydrolyzes peptide bonds in proteins. It is a member of the papain family of proteases and has been shown to activate peptides and inhibit ion channels, both of which are important for cell biology research. Antipain, an inhibitor of protein synthesis, is also used as a research tool in cell biology and biochemistry.

Bombesin is a small peptide that was first isolated from the skin of a frog, Bombina bombina, with homologs later found to be present in mammalian tissues, including the brain and gastrointestinal tract. It is a member of the bombesin-like peptide family, which includes several related peptides such as gastrin-releasing peptide (GRP) and neuromedin B.
Bombesin acts as a neuromodulator and regulates various physiological functions, including gastrointestinal motility and stimulation of gastrin release from G cells. It also plays a role in the regulation of cardiovascular function and neurotransmitter release. In addition, bombesin has been shown to stimulate the growth and proliferation of certain types of cancer cells, including prostate and lung cancer cells, through its interaction with bombesin receptors. It may therefore be used as a potential biomarker for certain cancers.

Custom research peptide; min purity 95%.

Suc-Ala-Ala-pNA is a synthetic peptide that has been shown to inhibit the activity of enzymes in the metabolic pathway of cholesterol biosynthesis. It also inhibits the activity of phospholipase A2 and cyclooxygenase, which are involved in arachidonic acid metabolism. Suc-Ala-Ala-pNA is a hydrophobic molecule that can be used as an inhibitor for enzymes such as esterases, aminopeptidases, amidases, carboxypeptidases, and proteases. Suc-Ala-Ala-pNA has been shown to have antiatherosclerotic properties because it inhibits the production of lipid peroxides.

MAL-dPEG®4-(m-dPEG®4)3 is a PEG compound with two different functional groups (also known as heterobifunctional). Unlike homobifunctional PEG compounds (same functional group on both ends), this type of compounds are more versatile as have two different anchor points. MAL-dPEG®4-(m-dPEG®4)3 is used as a linker and spacer to add a PEG moiety, via pegylation (a bioconjugation technique) to proteins, peptides, oligonucleotides, small molecules and nanoparticles.

A synthetic peptide for use as a blocking control in assays to test for specificity of MMP13 antibody, catalog no. 70R-5295

This product has disulfide bonds between Cys1-Cys15 and Cys3-Cys11 and is available as a 0.1mg vial. Big Endothelin-1 (Human, 1-38) is part of the full lengthed 29 amino acid peptide Big Endothlin-1 which is a precursor peptide of the vasoconstrictorEndothelin-1 (ET-1). ET-1 exhibits vasoconstrictive properties and is an activator of endothelin G-protein coupled receptors. Furthermore ET-1 is produced when inflammation, vascular stress or hypoxia occurs. In vivo Big Endothelin-1 has a greater half life compared to ET-1 and therefore makes it useful to study secretory activity in the endothelial system.
Overall Big Endothelin-1 (Human, 1-38) can be used as a research tool for studying protein interactions, receptor activation and function, and ligand binding. This peptide is also used in pharmacology to study the effects of therapeutic agents on receptor activity and expression.

A synthetic peptide for use as a blocking control in assays to test for specificity of MAPKAPK2 antibody, catalog no. 70R-10034

Custom research peptide; min purity 95%.

A synthetic peptide for use as a blocking control in assays to test for specificity of FAM20C antibody, catalog no. 70R-6352

A synthetic peptide for use as a blocking control in assays to test for specificity of ACAT2 antibody, catalog no. 70R-1083

A synthetic peptide for use as a blocking control in assays to test for specificity of EXOD1 antibody, catalog no. 70R-3113

A synthetic peptide for use as a blocking control in assays to test for specificity of SRPR antibody, catalog no. 70R-5029

A synthetic peptide for use as a blocking control in assays to test for specificity of C9orf68 antibody, catalog no. 70R-4309

The coronavirus (CoV) nucleoprotein is the major component of CoV structural proteins. The nucleoprotein has a critical role in virus assembly and RNA transcription. The nucleoprotein is essential in the formation of helical ribonucleoproteins and in regulating viral RNA synthesis. The nucleoprotein can also regulate infected host cellular mechanisms. It is highly expressed during infection and may induce protective immune responses against SARS-CoV and SARS-CoV-2.The nucleoprotein residues HIDAYKTFPPTEPKK (356-370) from SARS-CoV-2 have been identified as a T-cell epitope with a predicted HLA restriction. Immune targeting of confirmed epitopes may potentially offer protection against SARS-CoV-2 and help the development of vaccines for long-lasting immunity.

A synthetic peptide for use as a blocking control in assays to test for specificity of ACADS antibody, catalog no. 70R-2485

Anti IL-1alpha (Rat) Serum is a serum that provides an inhibitor for IL-1alpha. The serum is used in the study of peptides and cell biology. This serum is made from high purity, life science grade material and has been shown to be effective in inhibiting the activation of ion channels.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Myelin oligodendrocyte glycoprotein (MOG) is a myelin protein found in the central nervous system. MOG is a ligand for CD200, which is an inhibitory receptor expressed by astrocytes. It has been shown that MOG can induce the proliferation and differentiation of primary cultures of rat astrocytes in vitro. MOG induces the production of reactive oxygen species in mitochondria and increases the expression of acid-binding protein, which are both important factors in the demyelination process. MOG has also been implicated as a potential factor in the development of multiple sclerosis. Further research into this protein may lead to new treatments or cures for disorders such as encephalomyelitis, nervous system diseases, or even cancer.

CJC-1295 is a synthetic peptide, which is an analogue of growth hormone-releasing hormone (GHRH). It is synthesized through recombinant DNA technology, which allows for precise control over its sequence and length. This particular peptide is designed to bind to GHRH receptors in the pituitary gland. By activating these receptors, CJC-1295 stimulates the release of growth hormone (GH) into the bloodstream.The primary function of CJC-1295 is to influence the endocrine system, particularly enhancing the release of endogenous growth hormone. It achieves this by increasing the amplitude and frequency of GH pulses without affecting the natural negative feedback mechanisms that regulate GH production. This mode of action distinguishes CJC-1295 from other growth hormone therapies, as it promotes a more physiological pattern of hormone secretion.CJC-1295 is used in various scientific contexts, primarily in research focusing on growth hormone deficiencies, muscle wasting conditions, and certain metabolic disorders. Its ability to increase GH release also makes it a subject of interest in studies related to aging, tissue repair, and regeneration. The longer half-life of CJC-1295 compared to natural GHRH peptides further enhances its applications in research, allowing for more sustained and controlled experimentation.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Please enquire for more information about Fluorescein-6-carbonyl-Leu-Glu(OMe)-His-DL-Asp(OMe)-fluoromethylketone including the price, delivery time and more detailed product information at the technical inquiry form on this page

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

H-His-Arg-OH is a synthetic peptide that has been shown to have cytotoxic effects on mammalian cells. The H-His-Arg-OH peptide can be used for the treatment of heart disease and autoimmune diseases, such as rheumatoid arthritis. This peptide has been found to be resistant to congestive heart failure, which is caused by a number of factors, including hypertension and valvular stenosis. It has also been shown to have an immunoglobulin G1 (IgG1) genotype.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Extraordinary strength of the streptavidin-biotin interaction allows for efficient capturing of even highly dilute targets; however, it makes recovery of proteins from affinity resins challenging. Conventional methods to elute biotinylated proteins from immobilized avidin include the following: (i) denaturation of streptavidin by boiling the resin in a denaturing buffer that may include high concentrations of chaotropic salts, (ii) trypsin digestion of proteins while they are bound to the resin, or (iii) elution of proteins with excess free biotin. These protocols can co-elute contaminant proteins by releasing nonspecifically bound proteins and/or naturally biotinylated proteins concurrently with labeled proteins. In addition, some of these methods can cause elution of high levels of resin-based peptides along with the proteins of interest, resulting in further sample contamination.
Disulfide Biotin Azide probe eliminates a major limitation of the streptavidin-biotin affinity purification. This reagent contains a biotin moiety linked to an azide moiety through a spacer arm containing a cleavable disulfide linker. Captured biomolecules can be efficiently released under mild conditions (50 mM dithiothreitol, 10 mM 2-mercaptoethanol or 1% sodium borohydride) and the small molecular fragment (188.25 Da) left on the labeled protein following cleavage. These features make the cleavable probe especially attractive for use in biomolecular labeling and proteomic studies.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity